Sonelokimab for Biologic-Naive Psoriatic Arthritis

Sonelokimab for Biologic-Naive Psoriatic Arthritis
58%47%36%May 18May 19May 20May 21May 22May 23May 24May 25May 26May 27May 28May 27 • YES 46.0%May 28 • YES 47.8%
MoonLake Immunotherapeutics AG ($MLTX)
No stock close$19.05$17.53$16.00May 18May 19May 20May 21May 22May 23May 24May 25May 26May 27May 28May 18 • MLTX $16.44May 19 • MLTX $16.37May 20 • MLTX $17.05May 21 • MLTX $18.47May 22 • MLTX $18.19May 26 • MLTX $18.23May 27 • MLTX $18.41May 28 • MLTX $18.68

Will this trial show a positive result on Response rate of participants achieving at least a 50% improvement in the American College of Rheumatology criteria (ACR50)?

Paper Trading
Create account to trade
ClinicalNewsTrialPositionsReasoningOracle
Primary Completion
2/4/27
Study Completion
2/4/27
Sponsor
MoonLake Immunotherapeutics AG
Ticker
$MLTX
Type
Phase 3
Trial Status
Active Not Recruiting
Trial Size
960
NCT
NCT06641076
Trial Description
Sonelokimab is being tested in adults with active psoriatic arthritis who have not used biologic drugs, measuring joint symptom improvement after 16 weeks.